Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

11.98GBp
11:35am EDT
Change (% chg)

-0.06 (-0.50%)
Prev Close
12.04
Open
12.00
Day's High
12.00
Day's Low
11.60
Volume
2,514,361
Avg. Vol
8,204,356
52-wk High
13.19
52-wk Low
4.44

Chart for

About

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D... (more)

Overall

Beta: 0.04
Market Cap(Mil.): £394.08
Shares Outstanding(Mil.): 3,284.01
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 173.69 32.21
EPS (TTM): -0.00 -- --
ROI: -19.76 -0.70 13.05
ROE: -96.12 -2.69 14.90

BRIEF-Oxford Biomedica Announces ‍Proposed Placing To Raise About 20.5 Mln STG

* OXFORD BIOMEDICA PLC - ‍PROPOSED PLACING TO RAISE APPROXIMATELY £20.5 MILLION​

Mar 09 2018

Oxford BioMedica wins second $100 million gene therapy contract

LONDON Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

Feb 15 2018

Oxford BioMedica wins second $100 mln gene therapy contract

LONDON, Feb 15 Britain's Oxford BioMedica has won a second $100 million contract to supply gene therapy material, this time from Bioverativ, which agreed last month to be acquired by Sanofi for $11.6 billion.

Feb 15 2018

BRIEF-Oxford Biomedica Says ‍Kymriah Receives Priority Review For Adult DLBCL​

* SAYS ‍KYMRIAH RECEIVES PRIORITY REVIEW FOR ADULT DLBCL​ Source text for Eikon: Further company coverage:

Jan 17 2018

Earnings vs. Estimates